Related Experiment Video

Updated: Jun 4, 2026

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
06:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?

Dan G Duda1, Sergey V Kozin, Nathaniel D Kirkpatrick

  • 1Steele Laboratory, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA. duda@steele.mgh.harvard.edu

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|February 26, 2011
PubMed

Insights

Targeting the CXCL12 pathway with new agents may overcome cancer treatment resistance. These therapies can enhance the effectiveness of chemotherapy and targeted drugs, potentially improving patient survival.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Advanced cancer treatments include chemotherapy, radiotherapy, and molecularly targeted agents.
  • While beneficial, current therapies offer modest survival gains and limited efficacy in certain cancer types or settings.
  • Tumor resistance to therapies is a significant challenge in cancer management.

Purpose of the Study:

  • To review preclinical and clinical data on the role of the chemokine CXCL12 (SDF1α) pathway in cancer therapy resistance.
  • To explore the potential of anti-CXCL12 agents as sensitizers to enhance current cancer treatments.

Main Methods:

  • Review of recent preclinical studies investigating the CXCL12 pathway.
  • Analysis of clinical trial data for anti-CXCL12 agents (AMD3100, NOX-A12, CCX2066).
  • Examination of the CXCL12/CXCR4 and CXCL12/CXCR7 signaling pathways.

Main Results:

  • CXCL12 pathway activation contributes to resistance against conventional and targeted cancer therapies.
  • CXCL12 promotes cancer cell survival, invasion, and stem cell phenotype.
  • CXCL12 recruits bone marrow-derived cells, facilitating tumor recurrence and metastasis, and promotes angiogenesis.

Conclusions:

  • The CXCL12/CXCR4 and CXCL12/CXCR7 pathways are key mediators of therapeutic resistance in various cancers.
  • Anti-CXCL12 agents show promise in sensitizing tumors to existing therapies.
  • Targeting the CXCL12 pathway represents a potential strategy to improve outcomes for advanced cancer patients.

More Related Videos

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...